Smruthi Organics, a Rs.120 crore Solapur, Maharashtra-based pharma company, has received US FDA approval for its active pharmaceutical ingredients (API) unit II located at Chincholi. The company is engaged in manufacturing APIs like amlodipine besilate, carbidopa, metformin Hcl, norfloxacin, telmisartan. The US FDA approval will enable it to penetrate business in highly regulated and lucrative markets of Europe and USA.
Smruthi Organics' core competency is multi-step organic synthesis and large scale manufacturing of organic molecules. Its focus has always been API for the regulated markets. The company has been part of successful contract manufacturing and custom synthesis agreements with leading European, American and Japanese customers. It is currently expanding R&D to become a one-stop solution provider from concept to execution for all API including.